Ultragenyx (RARE) Reiterated at Buy by Truist Securities, Latest Data Gives Confidence that GTX-102 is Working
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $185.00 price target on Ultragenyx Pharma (NASDAQ: RARE), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
